← Return to ARSI PR wars: Nubeqa (Bayer) vs Erleada (J & J) lawsuit

Discussion
northoftheborder avatar

ARSI PR wars: Nubeqa (Bayer) vs Erleada (J & J) lawsuit

Prostate Cancer | Last Active: Mar 4 5:17am | Replies (36)
Comment receiving replies
Profile picture for Jeff Marchi @jeffmarc

@brianjarvis
Interesting how the last chart shows Darolutamide Is more effective than the other three drugs as far as overall survival is concerned for Castrate sensitive people.

Jump to this post

Replies to "@brianjarvis Interesting how the last chart shows Darolutamide Is more effective than the other three drugs..."
brianjarvis | @brianjarvis | Mar 2 12:13pm

@jeffmarc Though I would go by the clinical trial outcomes (rather than the legal arguments in court litigation), I also understand the difficulty in extrapolating those population outcomes to a specific patient’s outcome.

VIEW AND REPLY